Date:	2023/8/23
Your Name:_	Ken Onodera
Manuscript T	tle: <u>Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma</u>
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Isao Yokota
Manuscript T	itle: Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Yuki Matsumura
Manuscript T	itle: Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Kazuki Hayasaka
Manuscript T	itle:Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Satoshi Shiono
Manuscript T	itle:Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Country or a section of the sec	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23	
Your Name:	Jiro Abe	
Manuscript ¹	Title: <u>Efficacy</u> o	f Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript i	number (if knowr	0):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Hirotsugu Notsuda
Manuscript T	itle:Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:	Akira Sakurada
Manuscript T	itle: Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Country or a section of the sec	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
12	materials, drugs, medical writing, gifts or other	None	
	materials, drugs, medical writing, gifts or other services		
12	materials, drugs, medical writing, gifts or other services Other financial or non-	None	
	materials, drugs, medical writing, gifts or other services		
	materials, drugs, medical writing, gifts or other services Other financial or non-		
13	materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:
13	materials, drugs, medical writing, gifts or other services Other financial or non-financial interests	None	llowing box:

Date:	2023/8/23
Your Name:_	Hiroyuki Suzuki
Manuscript T	itle: <u>Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma</u>
Manuscript n	umber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	Ç ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
4.4	Stock or stock options	None	
11	otoon of otoon options		
11	olock of olock options		
11			
11	Receipt of equipment,	None	
	Receipt of equipment, materials, drugs, medical		
	Receipt of equipment, materials, drugs, medical writing, gifts or other		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:

Date:	2023	/8/23
Your Name:_		Yoshinori Okada
Manuscript T	Γitle:	Efficacy of Platinum-based Adjuvant Chemotherapy for EGFR-mutant Lung Adenocarcinoma
Manuscript r	numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	Ç ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
4.4	Stock or stock options	None	
11	otoon of otoon options		
11	olock of olock options		
11			
11	Receipt of equipment,	None	
	Receipt of equipment, materials, drugs, medical		
	Receipt of equipment, materials, drugs, medical writing, gifts or other		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box:
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- financial interests	None	llowing box: